Free Trial

2seventy bio Q1 2023 Earnings Report

2seventy bio logo
$2.61 -0.07 (-2.61%)
As of 02/21/2025 04:00 PM Eastern

2seventy bio EPS Results

Actual EPS
-$1.08
Consensus EPS
-$1.19
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

2seventy bio Revenue Results

Actual Revenue
$41.62 million
Expected Revenue
$19.30 million
Beat/Miss
Beat by +$22.32 million
YoY Revenue Growth
N/A

2seventy bio Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

2seventy bio Earnings Headlines

Weiss Ratings Reiterates Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)
Analysts Set 2seventy bio, Inc. (NASDAQ:TSVT) Price Target at $7.20
Elon Social Security shock?
“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One Boston based think tank believes it could have drastic impacts on your money and life in America.
See More 2seventy bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 2seventy bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 2seventy bio and other key companies, straight to your email.

About 2seventy bio

2seventy bio (NASDAQ:TSVT), a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

View 2seventy bio Profile

More Earnings Resources from MarketBeat